DOF和DCF方案治疗进展期胃癌的疗效分析  被引量:1

A Comparative Study of DOF Regimen and DCF Regimen for Advanced gastric Cancer

在线阅读下载全文

作  者:韩守恒[1] 戴文香[1] 伍尤华[1] 

机构地区:[1]南华大学附属第一医院肿瘤内科,湖南衡阳421001

出  处:《中南医学科学杂志》2012年第6期594-596,599,共4页Medical Science Journal of Central South China

摘  要:目的分析比较多西他赛联合奥沙利铂、氟尿嘧啶(DOF方案)与联合顺铂、氟尿嘧啶(DCF方案)治疗进展期胃癌(Advanced gastric cancer)患者的初步疗效和患者的耐受性。方法 75例晚期胃癌患者,分别接受DOF方案或DCF方案治疗,DOF组37例,DCF组38例。两组患者特征具有可比性(P﹥0.05)。结果两组均有35例可以评价疗效。DOF组有效率为45.71%(16/35),其中CR 2例;DCF组有效率为42.86%(15/35),其中CR 1例。DOF组中位无进展时间为5.6月,DCF组中位无进展时间为5.8月。DOF组中位生存期9.5月;DCF组中位生存期9.7月。两组毒性反应主要为骨髓抑制,胃肠道反应,肾毒性和神经毒性。结论 DOF方案和DCF方案治疗进展期胃癌疗效相似,但DOF方案比DCF方案的耐受性要好。Objective The efficacy and toxicity of docetaxel plus oxaliplatin and fluorouracil regimen and docetaxel plus cisplatin and fluorouracil regimen in the treatment of the cases with advanced gastric cancer were observed and com pared. Methods The total of 75 cases were enrolled in the investigation,37 cases received DOF regimen and 38 cases received DCF regimen. Two groups were well-matched with baseline disease characteristics(P 〉 0.05). Results 35 ca ses can be evaluated in DOF and DCF regimens respectively. In DOF group, the response rate was 45.71% (16/35) ,2 a chieved complete response (CR) ;In DCF group, the response rate was 42.86% (15/35), 2 achieved complete response (CR). The median time-to-progression was 5.6 months for DOF group and 5.8 months for DCF group. In DOF group, the median survival was 9.5 months ; In DCF group, the median survival was 9.7 months. The major toxic reactions in the two groups were marrow depression,gastrointestinal reaction,renal toxicity and neurotoxicity. Conclusions The efficacy was similar to DOF regimen and DCF regimen in the treatment of advanced non-small cell lung cancer, DOF regimen would be better tolerated than DCF regimen.

关 键 词:进展期胃癌 多西他赛 奥沙利铂 顺铂 氟尿嘧啶 

分 类 号:R735.2[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象